Stay updated with breaking news from Regkirona. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Celltrion Group announced today results for its cocktail therapy candidates including neutralisation data against the Omicron variant (B.1.1.529). The Phase I clinical trial is a randomised, double- blind and placebo- controlled trial designed to evaluate the safety, tolerability and pharmacokinetics of CT-P63 in 24 healthy subjects in Poland.1 The study met its primary objectives with data showing CT-P63 to be safe and well tolerated, with no significant drug- related adverse events (AEs). ....
Global sales of Celltrion s COVID-19 antibody-drug Regkirona begin ANI | Updated: May 12, 2021 07:56 IST Seoul [South Korea], May 12 (ANI/Global Economic): Worldwide sales of Regkirona (active ingredient: regdanvimab), a COVID-19 antibody drug developed by South Korean biopharmaceutical company Celltrion Inc, has begun. Celltrion Healthcare Co Ltd, the marketing arm of Celltrion, announced on Monday that it has signed a contract with a Pakistani state-owned company to export 100,000 vials of Regkirona. The total supply is a sufficient amount to administer to about 30,000 people. The contractee is a subsidiary of Pakistan Ordnance Factories (POF), the largest defense contractor under Pakistan s Ministry of National Defense. The plan is to administer the first batch to Pakistani soldiers and the public. ....